Allogene Therapeutics Inc (NYSE:ALLO) Q4 2018 Earnings Conference Call - Final Transcript

Mar 08, 2019 • 08:30 am ET

Previous

Allogene Therapeutics Inc (NYSE:ALLO) Q4 2018 Earnings Conference Call - Final Transcript

Share
Close

Loading Event

Loading Transcript

Presentation
Operator
Operator

Good morning, ladies and gentlemen. Thank you for standby, and welcome to Allogene Therapeutics' Fourth Quarter 2018 Conference Call. At this time all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time.

(Operator Instructions) Please be aware that today's conference call is being recorded.

I would now like to turn the conference over to Christine Cassiano, Chief Communications Officer. Ms. Cassiano, please go ahead.

Executive
Christine Cassiano

Thank you, operator and good morning. Before market opened today, Allogene issued a press release to provides the corporate update and financial results, for the fourth quarter and full year ended December 31, 2018. This press release is available on our website at www.allogene.com. We will also be discussing our ALLO-501 Phase I, clinical trial protocol and have posted on our website a slide, which provides an overview of the trial. This can be found in the Investors section under News & Events.

We remind listeners that today's call is being webcast on our website and will be available for replay.

Joining me on the call today are Dr. David Chang, President and Chief Executive Officer; and Dr. Eric Schmidt, Chief Financial Officer.

During today's call, we will be making certain forward-looking statements. These may include statements regarding the success and timing of our ongoing and planned clinical trials, regulatory filings, future research and development efforts, manufacturing capabilities and 2019 financial guidance among other things.

These forward-looking statements are based on current information, assumptions and expectations that are subject to change and involve a number of risks and uncertainties, that may cause actual results to differ, materially from those contained in the forward-looking statements. These and other risks are described in our periodic filings, made with the Securities and Exchange Commission, including our Form 10-Q for the quarter ended September 30, 2018, as well as our upcoming Form 10-K, for the year ended December 31st, 2018. You are cautioned not to place undue reliance on these forward-looking statements and the company disclaims any obligation to update such statements.

I will now turn the call over to Dr. David Chang.

Executive
David D. Chang

Thank you, Christine. Good morning, and thank you all for joining us today on Allogene's first quarterly call. We will keep our scripted comments relatively brief, as we look forward to any questions you may have on our ALLO-501 ALPHA trial and other business activities. 2018 was a very memorable year for us at Allogene, and we are very proud of what our team accomplished in just 10 short months, since we began the operations. From building a stellar executive management team, to our successful IPO and the IND-acceptance, for our first clinical candidate, we believe, we are making excellent and rapid progress and we plan to continue on that trajectory.

We are 100% focused on bringing allogeneic CAR T or as we refer to them AlloCAR T therapies, to market so that all appropriate patients have the opportunity to receive treatment. Every path we undertake at